TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.
Combined chemoimmunotherapy
Lung adenocarcinoma
PD-L1
Prospective observation study
Thyroid transcription factor 1
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
16
12
2022
revised:
28
02
2023
accepted:
02
03
2023
medline:
7
4
2023
entrez:
6
4
2023
pubmed:
7
4
2023
Statut:
epublish
Résumé
Lung adenocarcinoma with negative TTF-1 expression is believed to be a poor prognostic factor for certain systemic treatments. Nevertheless, the impact of TTF-1 expression on combined chemoimmunotherapy remains unclear. We aimed to investigate the relationship between tumor TTF-1 expression and the efficacy of combined chemoimmunotherapy in patients with advanced lung adenocarcinoma. This multicenter prospective observational study included 58 patients with advanced lung adenocarcinoma treated with combined chemoimmunotherapy across 10 institutions in Japan. The expression of TTF-1 in pretreatment tumors was determined using immunohistochemistry. The objective response rate of combined chemoimmunotherapy was significantly higher in TTF-1-positive groups than in TTF-1-negative groups ( TTF-1 positivity is associated with better clinical outcomes in patients with advanced lung adenocarcinoma treated with combined chemoimmunotherapy.
Identifiants
pubmed: 37020925
doi: 10.1016/j.jtocrr.2023.100494
pii: S2666-3643(23)00033-4
pmc: PMC10067944
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100494Informations de copyright
© 2023 The Authors.
Références
Clin Chim Acta. 2015 Dec 7;451(Pt B):208-14
pubmed: 25661085
Tumour Biol. 2017 Feb;39(2):1010428317691186
pubmed: 28218046
Sci Rep. 2016 Feb 25;6:19857
pubmed: 26912193
Lung Cancer. 2021 Sep;159:128-134
pubmed: 34333203
Eur J Cancer. 2021 Jun;150:63-72
pubmed: 33892408
Br J Cancer. 2019 Apr;120(9):903-912
pubmed: 30956278
Mol Clin Oncol. 2020 Sep;13(3):9
pubmed: 32754323
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Transl Lung Cancer Res. 2019 Dec;8(6):847-853
pubmed: 32010563
J Zhejiang Univ Sci B. 2012 Nov;13(11):855-66
pubmed: 23125078
J Clin Pathol. 2016 Feb;69(2):136-41
pubmed: 26281863
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Ann Oncol. 2019 Dec 1;30(12):1978-1984
pubmed: 31553438
Clin Lung Cancer. 2020 Nov;21(6):e607-e621
pubmed: 32620471
Vitam Horm. 2018;106:517-544
pubmed: 29407447
Immunity. 2018 Oct 16;49(4):764-779.e9
pubmed: 30332632
Oncoimmunology. 2021 Aug 2;10(1):1957603
pubmed: 34377595
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Thorac Oncol. 2021 Apr;16(4):653-664
pubmed: 33333328
JAMA Oncol. 2016 Sep 1;2(9):1217-22
pubmed: 27310809
PLoS One. 2017 Jul 3;12(7):e0180346
pubmed: 28671973
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Thorac Cancer. 2022 Aug;13(16):2309-2317
pubmed: 35808895
J Clin Invest. 2012 Dec;122(12):4388-400
pubmed: 23143308
Hum Pathol. 2003 Jun;34(6):597-604
pubmed: 12827614
Sci Rep. 2020 Oct 15;10(1):17495
pubmed: 33060826
Lung Cancer. 2016 Aug;98:51-58
pubmed: 27393506
PLoS One. 2014 Jul 08;9(7):e100837
pubmed: 25003505
Oncotarget. 2017 Jan 31;8(5):8738-8751
pubmed: 28060732